Angiodynamic IncANGO
Price$15.38

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $320.2M+9.5% YoYTTM through 31 May 2026
Net Income -$36.7MTTM through 31 May 2026
Free Cash Flow $508KTTM through 31 May 2026

Margins

Current
Gross Margin52.9%
EBITDA Margin-5.3%
Operating Margin-15.4%
Net Margin-11.5%

Returns

-18.1%ROE
-12.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.35x
Net Debt-$37.8Mnet cash position
Cash & Equivalents$53.9M

Quality Metrics

Altman Z-Score2.70
Piotroski F-Score4 / 9
FCF Margin0.2%
Rule of 405.5
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25'26
FY2026: $320.2M
Diluted EPS-$0.88TTM
'20'21'22'23'24'25'26
FY2026: $-0.88

Dividend

No dividend

Capital Allocation

R&D Spend$29.4M
Capex Intensity0.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.